# Nicholas G Nickols

List of Publications by Year
in descending order



| 64 | 3,133 | 201674 | 161849 |
|---|---|---|---|
| papers | citations | 27 h-index | 54 g-index |

| 65 | 65 | 65 | 3387 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT. Prostate Cancer and Prostatic Diseases, 2023, 26, 207-209. | 3.9 | 8 |
| 2 | Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. European Urology Oncology, 2022, 5, 100-103. | 5.4 | 18 |
| 3 | aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in <sup>18</sup>F-DCFPyL Images of Veterans with Prostate Cancer. Journal of Nuclear Medicine, 2022, 63, 233-239. | 5.0 | 25 |
| 4 | Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. Radiotherapy and Oncology, 2022, 166, 1-7. | 0.6 | 9 |
| 5 | Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System. JAMA Network Open, 2022, 5, e2144027. | 5.9 | 43 |
| 6 | Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. JAMA Oncology, 2022, 8, e216871. | 7.1 | 18 |
| 7 | Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncology, The, 2022, 23, 304-316. | 10.7 | 68 |
| 8 | Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison. Advances in Radiation Oncology, 2022, 7, 100944. | 1.2 | 1 |
| 9 | High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patientâ€“data Network Meta-analysis from the MARCAP Consortium. European Urology, 2022, 82, 106-114. | 1.9 | 19 |
| 10 | A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). European Urology, 2021, 80, 280-292. | 1.9 | 140 |
| 11 | The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. Prostate Cancer and Prostatic Diseases, 2021, 24, 135-139. | 3.9 | 11 |
| 12 | Doseâ€“response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. Radiotherapy and Oncology, 2021, 154, 207-213. | 0.6 | 24 |
| 13 | Prostate-specific Membrane Antigen Positron Emission Tomographyâ€“guided Radiotherapy. European Urology Focus, 2021, 7, 250-253. | 3.1 | 6 |
| 14 | High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors. Clinical Cancer Research, 2021, 27, 1505-1515. | 7.0 | 36 |
| 15 | False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 501-508. | 6.4 | 30 |
| 16 | Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. European Urology Oncology, 2021, 4, 327-330. | 5.4 | 3 |
| 17 | Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. European Urology Focus, 2021, 7, 238-240. | 3.1 | 31 |
| 18 | Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. BMC Cancer, 2021, 21, 512. | 2.6 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial. BMC Cancer, 2021, 21, 538. | 2.6 | 29 |
| 20 | Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Network Open, 2021, 4, e2115312. | 5.9 | 12 |
| 21 | Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. International Journal of Radiation Oncology Biology Physics, 2021, 110, 731-737. | 0.8 | 27 |
| 22 | Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. Prostate Cancer and Prostatic Diseases, 2021, , . | 3.9 | 8 |
| 23 | Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. European Urology, 2021, 80, 142-146. | 1.9 | 12 |
| 24 | Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series. Advances in Radiation Oncology, 2021, 6, 100759. | 1.2 | 1 |
| 25 | Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€"Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Network Open, 2021, 4, e2138550. | 5.9 | 18 |
| 26 | Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. JAMA Network Open, 2021, 4, e2139769. | 5.9 | 16 |
| 27 | Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. European Urology, 2020, 77, 3-10. | 1.9 | 18 |
| 28 | Gantry-Mounted Linear Acceleratorâ€"Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 404-411. | 1.2 | 6 |
| 29 | Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. European Urology, 2020, 77, 201-208. | 1.9 | 37 |
| 30 | Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Radiotherapy and Oncology, 2020, 151, 26-32. | 0.6 | 19 |
| 31 | The Impact of 18F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 1364-1369. | 1.2 | 5 |
| 32 | Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer. Frontiers in Oncology, 2020, 10, 539. | 2.8 | 29 |
| 33 | Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. European Urology, 2020, 78, 327-332. | 1.9 | 18 |
| 34 | Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 917-926. | 0.8 | 11 |
| 35 | Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. Frontiers in Oncology, 2020, 10, 786. | 2.8 | 3 |
| 36 | Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 930-935. | 0.8 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. Journal of Nuclear Medicine, 2020, 61, 1153-1160. | 5.0 | 94 |
| 38 | Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. International Journal of Radiation Oncology Biology Physics, 2019, 105, 149-154. | 0.8 | 9 |
| 39 | Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, 628-636. | 0.8 | 20 |
| 40 | Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer, 2019, 19, 291. | 2.6 | 17 |
| 41 | Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Network Open, 2019, 2, e188006. | 5.9 | 221 |
| 42 | Optimal patient selection for stereotactic body radiotherapy. Lancet Oncology, The, 2019, 20, e661. | 10.7 | 2 |
| 43 | Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes. JAMA Oncology, 2019, 5, 91. | 7.1 | 27 |
| 44 | Treatment of the primary tumor in metastatic prostate cancer. World Journal of Urology, 2019, 37, 2597-2606. | 2.2 | 11 |
| 45 | Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer, 2019, 19, 18. | 2.6 | 86 |
| 46 | Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 896. | 7.4 | 252 |
| 47 | Potential Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1714-1721. | 5.0 | 81 |
| 48 | The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 557-567. | 5.0 | 41 |
| 49 | Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. Journal of Nuclear Medicine, 2018, 59, 434-441. | 5.0 | 113 |
| 50 | <sup>68</sup>Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. Journal of Nuclear Medicine, 2018, 59, 230-237. | 5.0 | 226 |
| 51 | Spatial Mapping of Myeloid Cells and Macrophages by Multiplexed Tissue Staining. Frontiers in Immunology, 2018, 9, 2925. | 4.8 | 32 |
| 52 | Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. International Journal of Radiation Oncology Biology Physics, 2018, 101, 883-888. | 0.8 | 10 |
| 53 | Interference with DNA repair after ionizing radiation by a pyrrole-imidazole polyamide. PLoS ONE, 2018, 13, e0196803. | 2.5 | 4 |
| 54 | A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer. Cancer Research, 2017, 77, 2207-2212. | 0.9 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy, 2017, 16, 1106-1112. | 0.5 | 19 |
| 56 | Clinical Outcomes for Patients with Gleason Score 9â€“10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. European Urology, 2017, 71, 766-773. | 1.9 | 83 |
| 57 | SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. Practical Radiation Oncology, 2016, 6, 268-275. | 2.1 | 27 |
| 58 | Animal Toxicity of Hairpin Pyrrole-Imidazole Polyamides Varies with the Turn Unit. Journal of Medicinal Chemistry, 2013, 56, 7449-7457. | 6.4 | 30 |
| 59 | Antitumor activity of a pyrrole-imidazole polyamide. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1863-1868. | 7.1 | 111 |
| 60 | Activity of a Pyâ€“Im Polyamide Targeted to the Estrogen Response Element. Molecular Cancer Therapeutics, 2013, 12, 675-684. | 4.1 | 48 |
| 61 | Improved nuclear localization of DNA-binding polyamides. Nucleic Acids Research, 2007, 35, 363-370. | 14.5 | 208 |
| 62 | Modulating Hypoxia-Inducible Transcription by Disrupting the HIF-1â€“DNA Interface. ACS Chemical Biology, 2007, 2, 561-571. | 3.4 | 120 |
| 63 | Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 10418-10423. | 7.1 | 183 |
| 64 | Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 16768-16773. | 7.1 | 211 |